tutor2u A Level Economics Blog

Tracker Pixel for Entry

GlaxoSmithKline and Pfizer choose to collaborate on HIV drugs

Tuesday, November 03, 2009
Print Tweet This!Save to Favorites
Recommend on Google+

Here is an excellent highly relevant article on cooperative behaviour between oligopolistic giants. Two of the world’s biggest drugs companies GlaxoSmithKline and Pfizer have announced a plan to merge their HIV treatments in a joint venture. ViiV Healthcare is an attempt for both companies to limit the risks of costly races to find new profitable treatments for HIV/aids and give them an opportunity to counter the loss of the revenues as these companies lose patent protection and are open to competition from generic drug makers. It is a strong reminder of the very high fixed costs of research into new drugs; the long lead times between new drug development, testing and finally getting it to the market. And also the impact of the entry of generic drugs into markets once patent protection runs out. The new company has a 19% share of the global drugs market, in comparison to the Californian company Gilead’s 31%.

Drug firms’ collaboration pools HIV treatments (Independent)

IPO of HIV business is ‘up to shareholders’ (Telegraph)


blog comments powered by Disqus


ECONOMICS TEACHER RESOURCE NEWSLETTER

Join over 6,000 other Economics Teachers in the UK and around the world who receive the tutor2u regular Economics Resource Email Newsletter. Get special offers, first news of latest resources, teaching ideas, conferences and workshops + loads of great ideas for teaching economics from our blog authors.

*  Your Email Address:
*  Preferred Format:
    AS/A2 Economics Board:
    GCSE Economics Board:
*  Country:
    Full Name:
    Job / Position:
    Postcode:
    School / College:
    Town / City:
*  Enter the security code shown:

Blog RSS feed Blog RSS Feed
AS/A2 Econ Revision Notes AS/A2 Econ Revision Notes 


Login to the tutor2u Moodle VLE

Latest entries

Categories